Zhengye Biotechnology Holding Limited

NASDAQ:ZYBT

Drug Manufacturers - Specialty & Generic

Healthcare
$1.50 +1047.56%

+$7.31 today

Market cap
$71.09M
Beta
-2.17
P/E (TTM)
-36.3
EPS (TTM)
-$1.50
52W Low $0.62High $13.08

Volume 0.02M

Average 0.10M

ZYBT Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

Zhengye Biotechnology Holding LimitedNASDAQ: ZYBT

Income Tax Expense · Q4 FY2025 · quarter ended Dec 2025

Income tax expense of CN¥16.13M in Q4 FY2025

Q4 FY2025 income tax expense was CN¥16.13M. Over 3 fiscal years it compounded at +10.7% a year.

Context

  • Income tax expense amounted to 9.5% of revenue in FY2025, up 9.0 pp from a year earlier.
  • Income tax expense increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
CN¥16.13M+96.3% QoQ
Last fiscal yearDec 2025
CN¥11.1M+1100.8% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+1100.8%——
3-year CAGR+10.7%——
5-year CAGR——
10-year CAGR——

Income Tax Expense history

CNY · from the income statement

Latest · FY2025
11.1M CNY
Year-over-year change
+1100.8%
4-year CAGR
+13.9%

Income Tax Expense vs competitors

How ZYBT compares with its peers on the latest reported figures

  • Peers report in different currencies, so income tax expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +1100.8% is the highest of 5, against a peer median of +41.0%.
  • Income tax expense amounts to 9.5% of revenue for ZYBT, versus a peer median of 0.3%.
ZYBT Competitors
Income Tax Expense for ZYBT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ZYBTZhengye Biotechnology Holding LimitedFY2025CN¥11.1M CNY+1100.8%+10.7%9.5%
PDEXPro-Dex, Inc.LTM Mar 2026$4.09M USD+35.3%+40.0%5.5%
APYXApyx Medical CorporationLTM Mar 2026$364K USD+46.8%-9.7%0.7%
ONCYOncolytics Biotech Inc.LTM Mar 2026CA$170.54K CAD+63.3%+18.9%—
SRZNSurrozen, Inc.LTM Mar 2026$0 USD——0.0%
CRDLCardiol Therapeutics Inc.LTM Mar 2026CA$0 CAD———
SERASera Prognostics, Inc.LTM Mar 2026$0 USD——0.0%
TILInstil Bio, Inc.LTM Mar 2026$0 USD———
EXOZeXoZymes, Inc.LTM Mar 2026-$105.21K USD-10520600.0%——
Peer median (excluding ZYBT) —+41.0%+18.9%0.3%

Competitors are the stored peer set for ZYBT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CNY
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue214.07M260.27M211.65M186.36M116.36M
Cost of Revenue88.67M106.75M81.8M95.06M92.49M
Gross Profit125.39M153.52M129.86M91.3M23.87M
Gross Margin58.6%59.0%61.4%49.0%20.5%
Research & Development11.37M13.42M11.9M12.79M18.01M
Selling, General & Admin58.19M63.56M66.63M63.84M74.92M
Operating Expenses73.01M87.69M84.87M74.86M92.12M
Depreciation & Amortization16.01M18.8M23.91M24.16M25.96M
EBITDA70.12M85.55M72.1M42.6M(42.52M)
EBITDA Margin32.8%32.9%34.1%22.9%-36.5%
Operating Income52.38M65.83M44.99M16.44M(68.25M)
Operating Margin24.5%25.3%21.3%8.8%-58.7%
Interest Income112K114K312K231K96K
Interest Expense1.05M2.84M4.42M4.04M3.4M
Other Income / Expenses683K(1.92M)(1.22M)(2.05M)(3.62M)
Income Before Tax53.07M63.91M43.76M14.39M(71.87M)
Pre-Tax Margin24.8%24.6%20.7%7.7%-61.8%
Income Tax Expense6.6M8.17M6.25M924K11.1M
Net Income38.96M46.74M31.46M11.31M(69.78M)
Net Margin18.2%18.0%14.9%6.1%-60.0%
EPS (Basic)0.851.020.690.24(1.40)
EPS (Diluted)0.830.990.670.24(1.40)
Weighted Avg Shares45.67M45.67M45.67M47.17M47.35M
Weighted Avg Shares (Diluted)47.17M47.17M47.17M47.17M47.35M

Zhengye Biotechnology Holding Limited

NASDAQ:ZYBT

Intrinsic Alpha fair value

Locked

Current Price

$1.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.